A validated chiral LC method for the enantiomeric separation of repaglinide on amylose based stationary phase

A simple, isocratic, normal phase chiral HPLC method was developed and validated for the enantiomeric separation of repaglinicle, (S)-(+)-2-ethoxy-4-N []-(2-piperidinophenyl)-3-methyl- I -butyl] aminocarbonylmethyl] benzoic acid, an anticliabetic in bulk drug substance. The enantiomers of repaglinicle were resolved on a ChiralPak AD-H (amylose based stationary phase) column using a mobile phase consisting of n-hexane: 2-propanol:trifluoroacetic acid (95:5:0.2 v/v/v) at a flow rate of 1.0 mL min(-1). The resolution between the enantiomers was found to be not >3.5 in optimized method. The presence of trifluoroacetic acid in the mobile phase played an important role, in enhancing chromatographic efficiency and resolution between the enantiomers. The developed method was extensively validated and proved to be robust. The calibration curve for (R)-enantiomer showed excellent linearity over the concentration range of 900 ng mL(-1) (LOQ) to 6,000 ng mL(-1). The limit of detection and limit of quantification for (R)-enantiomer were 300 and 900 ng mL(-1), respectively. The percentage recovery of the (R)-enantiomer ranged between 98.3 and 101.05% in bulk drug samples of repaglinicle. Repaglinide sample solution and mobile phase were found to be stable up to,48 h. The developed method was found to be enantioselective, accurate, precise and suitable for quantitative determination of (R)-enantiomer in bulk drug substance.